This new list of the top 10 penny stocks to buy now includes some of the hottest tech, pharma, and high-yield investments to buy today.
When done correctly, penny stock investing can indeed be lucrative. A key benefit of investing in top penny stocks is the potential for big gains over a short period of time. Another is that an investment doesn't require a great deal of money.
Penny stocks, however, can be risky. Some are thinly traded. Some have wide bid/ask spreads. Financial reporting standards tend to be more lax than for their larger counterparts. That's why it's important to be prudent with any penny stock investment. And, limit orders are a must.
We put together a full list of penny stock investing tips here. Now here are the top 10 penny stocks worth a look now.
Top 10 Penny Stocks for Q2 2015
Top 10 Penny Stocks for Q2, No. 1: Genetic Technologies Ltd. (Nasdaq ADR: GENE) shares are up a stratospheric 157.08% year to date (as of March 30 close). The Australia-based company offers a range of genetic tests for breast, ovarian, bowel, uterine, and prostate cancer, as well as neurological diseases. In January, GENE announced that six new breast diagnosis/treatment centers will begin offering one of its tests to high-risk patients. We first told readers about GENE in early February. Shares have risen some 69% since then.
Top 10 Penny Stocks for Q2, No. 2: China BAK Battery Inc. (Nasdaq: CBAK) develops, manufactures, and sells high-power lithium batteries internationally. Its products are used in electric vehicles, electric tools, energy storage, uninterruptible power supply, and other high-power applications. The company has an impressive record of earnings per share growth, growth in net income, and good cash flow from operations. Shares are up a meteoric 90.81% year to date.
Continue reading for seven more top penny stocks (for Money Morning Members only)...
Top 10 Penny Stocks for Q2, No. 3: ArQule Inc. (Nasdaq: ARQL) is a clinical-stage biotechnology company focused on cancer therapeutics. Its lead product candidate tivantinib is in Phase 3 clinical trials for the treatment of non-small-cell lung and liver cancer. Tivantinib is also being studied to work in combination with other anti-cancer therapies in various diseases. ARQL has a research collaboration with global pharmaceutical giant Daiichi Sankyo Co. Shares are up a blistering 84.02% year to date.
Top 10 Penny Stocks for Q2, No. 4: Ecosphere Tech Inc. (OTCMKTS: ESPH) develops environmental water treatment solutions for the global industrial markets. The Florida-based company offers mobile water treatment and recycling services to energy exploration companies via its patented Ozonix technology. The treatment system provides a cost efficient and environmentally friendly process for cleaning and recycling fluids contaminated during fracking (hydraulic fracturing - the technique used to recover gas and oil from shale rock). Shares are up a sizzling 79.49% year to date.
Top 10 Penny Stocks for Q2, No. 5: Synthetics Biologics Inc. (NYSEMKT: SYN) is a biotech company focused on developing novel therapies that target specific pathogens responsible for causing serious infections and diseases. Product candidates include Trimesta. The drug has completed Phase 2 clinical trials for the treatment of relapsing-remitting multiple sclerosis and cognitive MS dysfunction. Shares are up 54.09% year to date.
Top 10 Penny Stocks for Q2, No. 6: Euro Tech Holdings Company Ltd. (Nasdaq: CLWT) distributes advanced water treatment equipment for commercial and governmental customers in Hong Kong and the People's Republic of China. The company reported Monday its subsidiary, PACT Environmental Technology Company Ltd., has been accepted for use as an alternate management system in U.S. waters. In a move suggesting CLWT believes shares are undervalued, its Board recently approved a 60,000 share repurchase program. Shares are up 32.37% year to date.
Top 10 Penny Stocks for Q2, No. 7: CASI Pharmaceuticals Inc. (Nasdaq: CASI) is a clinical-stage pharmaceutical company developing treatments for cancer and other diseases in the United States and China. On March 30, CASI announced the China Food and Drug Administration approved its application to conduct a Phase 2 global clinical trial in ovarian clear cell carcinoma patients for its proprietary drug candidate ENMD-2076. Shares are up 17.89% year to date.
[epom key="ddec3ef33420ef7c9964a4695c349764" redirect="" sourceid="" imported="false"]
Top 10 Penny Stocks for Q2, No. 8: ModSys International Ltd.'s (Nasdaq: MDSY) technologies and services allow businesses to migrate from their legacy mainframe and distributed IT infrastructures to modern environments and programming languages. On March 26, the Seattle-based company announced a new technology that allows quicker time to market for critical software updates. MDSY jumped 35.6% on the news.
Top 10 Penny Stocks for Q2, No. 9: Resource Capital Corp. (NYSE: RSO) is a diversified U.S. real estate investment trust. It focuses on originating, holding, and managing commercial mortgage loans and other commercial real estate-related debt and equity investments. As a REIT, RSO distributes 100% of its taxable income. In February, RSO reported Q4 funds from operation (FFO) of $0.17. That was $0.02 better than forecasts. At $4.54, shares trade at a modest price-to-earnings ratio of 13.44 and yield 14.1%.
Top 10 Penny Stocks for Q2, No. 10: Eyegate Pharmaceuticals Inc. (OTCBB: EYEG) is a clinical-stage specialty pharmaceutical company focused on treating eye disease. The company's EGP-437 has completed Phase 3 clinical trials for the treatment of non-infectious anterior uveitis, a form of eye inflammation. EGP-437 is also being developed for dry eye, cataract surgery, and macular edema. Also in EYEG's pipeline is Eyegate II, a drug delivery system. The company says the system has significant potential in ophthalmic drug administration. As the only non-invasive delivery system, it offers benefits for both clinicians and patients. The company considers the advantages over traditional methods, including self-administered eye drops and intravitreal injections, are compelling. Based in Waltham, Mass., EYEG went public on Feb. 13 at $6. Shares slipped to a low of $2.74 over the last couple of weeks. However, EYEG jumped 11.11% to $3.50 Monday along with the overall healthcare sector.
For a bonus five penny stock picks for 2015, go here.
For more investing tips for 2015, try our best investing strategy guide and our top wearable tech stocks.